Document is current
Any future updates will be listed below
-
Authors
Darricau, Morgane
Kulifaj, Valentine
Arotcarena, Marie-Laure
Li, Qin
Katsinelos, Taxiarchis
McEwan, William A.
Xilouri, Maria
Dehay, Benjamin
Bezard, Erwan
Planche, Vincent
-
Funding
Funding for this research was provided by:
Clément Fayat Foundation
the Innovative Medicines Initiative 2 Joint Undertaking (116060 (IMPRiND), 116060 (IMPRiND), 116060 (IMPRiND))
Wellcome Trust and the Royal Society (206248/Z/17/Z)
Michael J. Fox Foundation for Parkinson's Research
French government in the framework of the University of Bordeaux’s IdEx “Investments for the Future” program (GPR BRAIN_2030)
Bettencourt-Schueller Foundation
PSP-France Foundation
Center of Excellence for Neurodegenerative Diseases in Bordeaux
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 5 April 2025
First Online: 13 April 2025
Competing interests
: E.B. is a director and shareholder of Motac Neuroscience Ltd. During the past 3 years, V.P. was a local unpaid investigator or sub-investigator for clinical trials granted by Novo Nordisk, Biogen, Janssen, and Alector. V.P. served as a consultant for Motac Neuroscience Ltd, outside the submitted work. Other authors declare no competing interests.
